Magali Richard serves as DBV’s Chief Strategy Officer, assisting in the definition and implementation of strategic objectives, overseeing business development and strategic planning. She is a member of the Executive Committee. Ms. Richard joined DBV in October 2016 and has been responsible for Business Development and Portfolio Strategy. Prior to DBV, she was at the Boston Consulting Group (BCG), where she acted as Principal and member of the Biopharma Practice. Ms. Richard has broad expertise in the pharma industry, including corporate strategy and M&A, R&D portfolio definition, manufacturing strategy or development of innovative partnerships with Pharma and Biotechs. Prior to BCG, she was a Scientist at Biomarin Pharmaceutical. She graduated from École Polytechnique in Paris and from École Nationale des Mines de Paris. She also holds a PhD in Molecular Biology from Université Pierre & Marie Curie in France.